Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could dupilumab help Hard-to-Treat asthma patients?

NCT ID NCT05564078

Completed Disease control Sponsor: McMaster University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether dupilumab, a drug that blocks certain immune signals, can reduce signs of autoimmunity in the airways of people with severe asthma. 30 patients were followed for 4 months. The goal was to see if this approach could help those who don't get better with standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Dupilumab
What this could lead to
If successful, this could point toward a treatment for severe asthma patients who don't respond to standard therapies.
What could go wrong
This is a small, completed observational study with only 30 participants. Results may not apply to all severe asthmatics, and the benefit seen in markers may not translate to better symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AIRWAY AUTO IMMUNITY IN ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma pulmonary eosinophilia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AIRWAY AUTO IMMUNITY IN ASTHMA

Contacts and locations

Locations

  • The Research Institute of St. Joe's Hamilton

    Hamilton, Ontario, L8N4A6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.